MAP7D2

Summary

MAP7D2 (MAP7 domain containing 2, HGNC:25899) is a protein-coding gene on chromosome Xp22.12, encoding MAP7 domain-containing protein 2 (Q96T17). Microtubule-stabilizing protein that plays a role in the control of cell motility and neurite outgrowth via direct binding to the microtubule.

Predicted to enable kinesin binding activity and microtubule binding activity. Predicted to be involved in axon development and microtubule cytoskeleton organization. Predicted to be located in axon; microtubule cytoskeleton; and midbody. Predicted to be active in microtubule cytoskeleton.

Source: NCBI Gene 256714 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 189 total
• MANE Select transcript: NM_001168465

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25899
Approved symbol	MAP7D2
Name	MAP7 domain containing 2
Location	Xp22.12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14503
Ensembl gene	ENSG00000184368
Ensembl biotype	protein_coding
OMIM	301121
Entrez	256714

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 16 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000379643, ENST00000379651, ENST00000443379, ENST00000452324, ENST00000466145, ENST00000875378, ENST00000875379, ENST00000875380, ENST00000918363, ENST00000970001, ENST00000970005, ENST00000970007, ENST00000970009, ENST00000970012, ENST00000970014, ENST00000970016, ENST00000970017

RefSeq mRNA: 4 — MANE Select: NM_001168465 NM_001168465, NM_001168466, NM_001168467, NM_152780

CCDS: CCDS14195, CCDS55384, CCDS55385, CCDS55386

Canonical transcript exons

ENST00000379643 — 17 exons

Exon	Start	End
ENSE00001318278	20056680	20056791
ENSE00001481939	20050824	20050946
ENSE00001673481	20044364	20044524
ENSE00001691197	20010777	20011052
ENSE00001694127	20063414	20063577
ENSE00001698009	20012349	20012535
ENSE00001734976	20025681	20025952
ENSE00001763917	20042502	20042629
ENSE00001780169	20016094	20016325
ENSE00001819468	20006713	20008398
ENSE00002257073	20052878	20052988
ENSE00002535546	20116750	20116907
ENSE00003459943	20015223	20015327
ENSE00003538965	20013569	20013625
ENSE00003608023	20013054	20013132
ENSE00003670120	20024951	20025083
ENSE00003683678	20064728	20064805

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 97.46.

FANTOM5 (CAGE): breadth broad, TPM avg 4.1087 / max 325.6449, expressed in 356 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198670	2.6194	304
198669	0.3661	112
198672	0.3197	100
198663	0.2198	48
198664	0.2189	51
198666	0.1263	32
198665	0.1019	32
198671	0.0702	41
198667	0.0447	11
198668	0.0217	8

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	97.46	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.25	gold quality
endothelial cell	CL:0000115	96.78	gold quality
middle temporal gyrus	UBERON:0002771	96.47	gold quality
pons	UBERON:0000988	95.52	gold quality
dorsal root ganglion	UBERON:0000044	95.12	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.90	gold quality
primary visual cortex	UBERON:0002436	93.55	gold quality
substantia nigra pars compacta	UBERON:0001965	93.02	gold quality
corpus epididymis	UBERON:0004359	92.62	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.53	gold quality
prefrontal cortex	UBERON:0000451	91.35	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.46	gold quality
frontal cortex	UBERON:0001870	89.71	gold quality
substantia nigra pars reticulata	UBERON:0001966	89.71	gold quality
occipital lobe	UBERON:0002021	89.69	gold quality
superior frontal gyrus	UBERON:0002661	89.65	gold quality
postcentral gyrus	UBERON:0002581	89.64	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.45	gold quality
neocortex	UBERON:0001950	89.03	gold quality
cerebellar cortex	UBERON:0002129	88.27	gold quality
right frontal lobe	UBERON:0002810	88.27	gold quality
cerebellar vermis	UBERON:0004720	88.22	gold quality
cerebellar hemisphere	UBERON:0002245	88.20	gold quality
parietal lobe	UBERON:0001872	88.19	gold quality
cerebellum	UBERON:0002037	88.18	gold quality
lateral globus pallidus	UBERON:0002476	88.11	gold quality
anterior cingulate cortex	UBERON:0009835	88.07	gold quality
superior vestibular nucleus	UBERON:0007227	87.92	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.66	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	29.49
E-ANND-3	no	4.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting MAP7D2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-561-3P	99.64	70.90	3647

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	map7d2b	ENSDARG00000045316
danio_rerio	map7d2a	ENSDARG00000068480
mus_musculus	Map7d2	ENSMUSG00000041020
rattus_norvegicus	Map7d2	ENSRNOG00000005176
drosophila_melanogaster	ens	FBGN0264693

Paralogs (3): MAP7D1 (ENSG00000116871), MAP7D3 (ENSG00000129680), MAP7 (ENSG00000135525)

Protein

Protein identifiers

MAP7 domain-containing protein 2 — Q96T17 (reviewed: Q96T17)

All UniProt accessions (6): A0A0K1JRJ6, A0A0K1JS24, A0A0M3R6J9, A0A0M4F6E1, A0A0M4FLI9, Q96T17

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule-stabilizing protein that plays a role in the control of cell motility and neurite outgrowth via direct binding to the microtubule. Acts as a critical cofactor for kinesin transport. In the proximal axon, regulates kinesin-1 family members, KIF5A, KIF5B and KIF5C recruitment to microtubules and contributes to kinesin-1-mediated transport in the axons.

Subunit / interactions. Interacts (via N-terminus) with microtubules; facilitates microtubule stabilization. Interacts with kinesin-1 family members, KIF5A, KIF5B and KIF5C.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Midbody. Cell projection. Neuron projection. Axon.

Similarity. Belongs to the MAP7 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q96T17-1	1	yes
Q96T17-2	2
Q96T17-3	3
Q96T17-4	4
Q96T17-5	5

RefSeq proteins (4): NP_001161937, NP_001161938, NP_001161939, NP_689993 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008604	MAP7_fam	Family
IPR051483	MAP7_domain-containing	Family

Pfam: PF05672

UniProt features (28 total): compositionally biased region 7, splice variant 7, region of interest 5, sequence conflict 4, sequence variant 2, chain 1, modified residue 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96T17-F1	64.09	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 99 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GOBP_NEUROGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOCC_CENTROSOME, LIAO_METASTASIS, RICKMAN_HEAD_AND_NECK_CANCER_A, GOCC_NEURON_PROJECTION, ZHANG_BREAST_CANCER_PROGENITORS_UP, GOBP_CELL_PROJECTION_ORGANIZATION, VECCHI_GASTRIC_CANCER_EARLY_DN, ATGTCAC_MIR489, RIGGI_EWING_SARCOMA_PROGENITOR_UP, HOXA4_Q2, GOCC_MIDBODY, GOCC_AXON

GO Biological Process (2): microtubule cytoskeleton organization (GO:0000226), axon development (GO:0061564)

GO Molecular Function (2): microtubule binding (GO:0008017), kinesin binding (GO:0019894)

GO Cellular Component (9): centrosome (GO:0005813), microtubule (GO:0005874), microtubule cytoskeleton (GO:0015630), axon (GO:0030424), midbody (GO:0030496), neuron projection (GO:0043005), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoskeleton organization	1
microtubule-based process	1
neuron projection development	1
tubulin binding	1
cytoskeletal protein binding	1
centriole	1
microtubule organizing center	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
cytoskeleton	1
neuron projection	1
plasma membrane bounded cell projection	1
intracellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1480 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAP7D2	NUTM2G	Q5VZR2	590
MAP7D2	TRIM46	Q7Z4K8	505
MAP7D2	RTL9	Q8NET4	505
MAP7D2	NUGGC	Q68CJ6	452
MAP7D2	SCOC	Q9UIL1	433
MAP7D2	RALGPS1	Q5JS13	427
MAP7D2	BCLAF3	A2AJT9	417
MAP7D2	BMERB1	Q96MC5	416
MAP7D2	GALK2	Q01415	402
MAP7D2	MAPK1IP1L	Q8NDC0	399
MAP7D2	BTF3L4	Q96K17	393
MAP7D2	FOXL2NB	Q6ZUU3	376
MAP7D2	POU2AF3	A8K830	362
MAP7D2	NECAP2	Q9NVZ3	355
MAP7D2	PABIR2	Q7Z309	354

IntAct

150 interactions, top by confidence:

A	B	Type	Score
EFNB2	FAM171A2	psi-mi:“MI:0914”(association)	0.530
KIAA0753	OFD1	psi-mi:“MI:2364”(proximity)	0.480
MAP7D2	HTRA3	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PDZD7	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PDZK1	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	TAX1BP3	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	NHERF2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
APBA3	MAP7D2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	LRRC7	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PDZRN4	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PCLO	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	LIMK2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	SNTG1	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	GIPC2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	ARHGEF11	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	LIN7A	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	ARHGAP21	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	FRMPD2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	LNX2	psi-mi:“MI:0407”(direct interaction)	0.440
MAP7D2	WHRN	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (102): MAP7D2 (Affinity Capture-MS), MAP7D2 (Affinity Capture-MS), MAP7D2 (Affinity Capture-MS), MAP7D2 (Proximity Label-MS), MAP7D2 (Proximity Label-MS), MAP7D2 (Proximity Label-MS), MAP7D2 (Proximity Label-MS), MAP7D2 (Proximity Label-MS), MAP7D2 (Proximity Label-MS), KIF20A (Affinity Capture-MS), BEND3 (Affinity Capture-MS), NEURL4 (Affinity Capture-MS), HERC2 (Affinity Capture-MS), USP20 (Affinity Capture-MS), MAP7D2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I5ZM56, A2AG50, A2AI08, A2AJI0, A5D7K1, D4A4L4, E1C2Q8, F1LR10, O00515, O14529, O75128, O88573, O88735, P51825, P57016, Q14244, Q32LQ1, Q3KQU3, Q3U2K0, Q5JTD0, Q5NBX1, Q5PR69, Q5R7F9, Q5XHX2, Q5ZIA2, Q5ZJJ1, Q68DK7, Q6IPM2, Q6NV74, Q6NZF1, Q6PDH0, Q6PDM1, Q6PG95, Q6ZU35, Q86UU1, Q8CCJ4, Q8K124, Q8N7J2, Q8TD55, Q96PV7

Diamond homologs: A0A8I5ZM56, A2AG50, A2AJI0, D4A4L4, O88735, Q14244, Q3KQU3, Q5R7F9, Q5ZIA2, Q96T17

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 120 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Negative regulation of NMDA receptor-mediated neuronal transmission	6	44.7×	3e-07
Ras activation upon Ca2+ influx through NMDA receptor	5	39.1×	1e-05
Unblocking of NMDA receptors, glutamate binding and activation	5	37.2×	1e-05
Long-term potentiation	5	32.6×	2e-05
Assembly and cell surface presentation of NMDA receptors	9	31.3×	1e-09
Neurexins and neuroligins	10	27.0×	9e-10
Protein-protein interactions at synapses	6	21.8×	2e-05
RHOC GTPase cycle	5	10.0×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	11	57.1×	2e-14
protein localization to synapse	6	41.0×	1e-06
receptor clustering	7	39.0×	2e-07
regulation of postsynaptic membrane neurotransmitter receptor levels	7	31.0×	6e-07
cell-cell adhesion	10	9.1×	2e-05
protein-containing complex assembly	8	8.1×	5e-04
nervous system development	11	4.5×	2e-03
protein transport	10	3.9×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

189 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	107
Likely benign	13
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3056 predictions. Top by Δscore:

Variant	Effect	Δscore
X:20010771:CTGTA:C	donor_loss	1.0000
X:20010772:TGTAC:T	donor_loss	1.0000
X:20010773:GTACC:G	donor_loss	1.0000
X:20010774:TACC:T	donor_loss	1.0000
X:20010775:A:T	donor_loss	1.0000
X:20010776:C:CA	donor_loss	1.0000
X:20011048:CAGGA:C	acceptor_gain	1.0000
X:20011049:AGGA:A	acceptor_gain	1.0000
X:20011050:GGA:G	acceptor_gain	1.0000
X:20011053:C:CC	acceptor_gain	1.0000
X:20012345:ATACC:A	donor_loss	1.0000
X:20012350:T:TA	donor_gain	1.0000
X:20012355:T:TA	donor_gain	1.0000
X:20012533:TTT:T	acceptor_gain	1.0000
X:20012536:C:CC	acceptor_gain	1.0000
X:20012541:C:CT	acceptor_gain	1.0000
X:20012542:G:T	acceptor_gain	1.0000
X:20013050:TCA:T	donor_loss	1.0000
X:20013051:CA:C	donor_loss	1.0000
X:20013052:A:AC	donor_gain	1.0000
X:20013052:A:C	donor_loss	1.0000
X:20013052:AC:A	donor_gain	1.0000
X:20013052:ACC:A	donor_gain	1.0000
X:20013053:C:CC	donor_gain	1.0000
X:20013053:C:G	donor_loss	1.0000
X:20013053:CC:C	donor_gain	1.0000
X:20013053:CCC:C	donor_gain	1.0000
X:20013053:CCCA:C	donor_gain	1.0000
X:20013053:CCCAT:C	donor_gain	1.0000
X:20013129:CTTT:C	acceptor_gain	1.0000

AlphaMissense

5002 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:20013612:A:C	I547S	0.999
X:20013612:A:G	I547T	0.999
X:20063539:C:G	A83P	0.999
X:20064751:C:G	R62P	0.999
X:20013623:T:A	R543S	0.998
X:20013623:T:G	R543S	0.998
X:20015229:T:A	R540S	0.998
X:20015229:T:G	R540S	0.998
X:20064753:T:A	R61S	0.998
X:20064753:T:G	R61S	0.998
X:20013602:T:A	R550S	0.997
X:20013602:T:G	R550S	0.997
X:20013609:A:G	M548T	0.997
X:20063455:C:G	A111P	0.997
X:20063481:C:G	R102P	0.997
X:20063505:C:G	R94P	0.997
X:20063571:C:G	R72P	0.997
X:20064764:C:G	A58P	0.997
X:20013612:A:T	I547N	0.996
X:20064754:C:G	R61T	0.996
X:20064774:C:A	R54S	0.996
X:20064774:C:G	R54S	0.996
X:20011052:A:C	S650R	0.995
X:20011052:A:T	S650R	0.995
X:20012350:T:G	S650R	0.995
X:20013596:C:A	R552S	0.995
X:20013596:C:G	R552S	0.995
X:20013608:C:A	M548I	0.995
X:20013608:C:G	M548I	0.995
X:20013608:C:T	M548I	0.995

dbSNP variants (sampled 300 via entrez): RS1000001636 (X:20096442 A>G), RS1000008761 (X:20034271 C>A,T), RS1000066829 (X:20056834 C>G,T), RS1000082521 (X:20086754 A>G), RS1000096944 (X:20049147 C>T), RS1000128049 (X:20048811 C>T), RS1000232778 (X:20114051 C>T), RS1000250938 (X:20114281 C>T), RS1000288707 (X:20038494 C>A,G), RS1000319174 (X:20026983 A>C), RS1000417356 (X:20104130 A>C), RS1000429979 (X:20024724 T>A), RS1000435930 (X:20112963 G>C), RS1000447628 (X:20103972 C>T), RS1000486079 (X:20104658 T>A,G)

Disease associations

OMIM: gene MIM:301121 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
Benzo(a)pyrene	affects methylation, increases expression	3
sodium arsenite	increases expression	2
belinostat	decreases expression, affects cotreatment	2
Formaldehyde	decreases expression, increases expression	2
FR900359	affects phosphorylation	1
kojic acid	decreases expression	1
trichostatin A	decreases expression, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
aflatoxin B2	increases methylation	1
hydroquinone	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
ICG 001	decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, increases expression, affects cotreatment	1
licochalcone B	increases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Panobinostat	decreases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Caffeine	decreases phosphorylation	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	affects cotreatment, increases expression	1
Demecolcine	increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Testosterone	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vanadates	decreases expression	1
Cyclosporine	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.